ORIGINAL ARTICLE

Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension

Wenjun He1,2 | Xi Su1,3 | Lingdan Chen1 | Chunli Liu1 | Wenju Lu1 | Tao Wang1 | Jian Wang1,4

1State Key Laboratory of Respiratory Diseases, Guangdong Key Laboratory of Vascular Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
2Department of Pulmonary Medicine, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands
3Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
4Division of Cardiology, Department of Medicine, University of California, San Diego, California, USA

Abstract

Background: Peripheral blood mononuclear cells (PBMCs) play an important role in the pathogenesis of pulmonary arterial hypertension (PAH). However, the specific roles of PBMCs in the development and progression of idiopathic PAH (IPAH) have not been fully understood.

Methods: Here, differentially expressed genes (DEGs) of PBMCs or lung tissues between IPAH patients and healthy controls were identified via bioinformatics analysis of Gene Expression Omnibus (GEO) datasets GSE33463 and GSE48149, respectively. Subsequently, extensive target prediction and network analysis were performed to assess protein–protein interaction (PPI) networks, Gene Ontology (GO) terms, and pathway enrichment for DEGs. Co-expressed DEGs between PBMCs and lung tissues coupled with corresponding predicted miRNAs involved in PAH were also assessed. We identified 251 DEGs in PBMCs and 151 DEGs in lung tissue samples from IPAH. PDK4, RBPMS2, and PDE5A expression were altered in both PBMCs and lung tissues from IPAH patients compared to healthy control.

Results: CXCL8, JUN, TLR8, IL1B, and TLR7 could be implicated as the hub genes in PBMCs, whereas ENO1, STAT1, CXCL10, GIP, and IRF1 in lung tissues. Finally, co-expressed DEGs of PDK4, RBPMS2, and PDE5A coupled with corresponding predicted miRNAs, especially miR-103a-3p, miR-185-5p, and miR-515-5p, are significantly associated with IPAH.

Conclusion: Our findings collectively suggest that the expression levels of PDK4, RBPMS2, and PDE5A in PBMCs are associated with the expression of these genes.
1 | INTRODUCTION

Idiopathic Pulmonary Arterial Hypertension (IPAH) is a rare and progressive disease with a poor prognosis, characterized by a progressive increase of pulmonary artery (PA) pressure and pulmonary vascular resistance (PVR) (Keating, 2016; Lau et al., 2017; Maron & Diagnosis, 2016). Although the mechanisms of IPAH remain unknown, there is growing evidence indicating that peripheral blood mononuclear cells (PBMCs) contribute to the pathogenesis of IPAH (Cheadle et al., 2012; Hoffmann et al., 2016; Risbano et al., 2010; Sarrion et al., 2015). Circulating PBMCs include lymphocytes, monocytes, stem cells, and other cell types. Compared to lung tissues, PBMCs can be collected from a broader range of patients; thus, PBMCs are used to study biomarkers for various diseases (Baine et al., 2012; Castaldo et al., 2019; Goleva et al., 2019; Guo et al., 2019; Yang et al., 2016). Lung tissues contain vessels and provide the microenvironment for pulmonary vascular cells, which are pathologically changed in pulmonary hypertension.

The gene expression analysis in lung homogenates may provide insight into genes involved in vascular remodeling in IPAH patients (Hoffmann et al., 2016; Yuan et al., 2016). However, lung tissues are not available from most of IPAH patients. Numerous studies suggest that PBMCs infiltrate lung tissues and play an important role in the pathogenesis of PH (Cheadle et al., 2012; Chesne et al., 2014; Risbano et al., 2010; Sarrion et al., 2015). Elevated numbers of inflammatory cells have been observed in the lungs of patients with IPAH. The recruited inflammatory cells can release mediators to directly change the vascular microenvironment, promoting the proliferation of pulmonary smooth muscle cells and recruiting more circulating inflammatory cells, further aggravating the progress of the disease (Hassoun et al., 2009; Hoffmann et al., 2011; Marsh et al., 2018; Perros et al., 2007; Pienn et al., 2018; Savai et al., 2012). PBMCs play a critical role in activating the innate immune response, which can migrate into the lung tissue (Cheadle et al., 2012; Foris et al., 2016; Khan & Kaithara, 2019; Lenna et al., 2013; Yamamoto, 2011; Yeager et al., 2012). However, the mechanism of how circulating inflammatory cells is recruited to lung tissues and what relations between PBMCs and lung tissues are unknown. To our knowledge, high-throughput technologies such as microarray expression profiles of PBMCs and lung tissues have provided powerful weapons for the diagnosis and prognosis of IPAH patients. Therefore, to make full use of expression profiles data of PBMCs and lung tissues from IPAH patients and better understand the pathogenesis of IPAH, we utilized bioinformatics analysis to explore hub genes and the critical mechanism of IPAH.

Here, we hypothesized that transcriptome changes between PBMCs and lung tissues contribute to the recruitment of inflammation cells, the changes of the vascular microenvironment, and pulmonary vascular remodeling. Thus, in this study, we conducted a bioinformatics analysis for the transcriptome in PBMCs and lung tissues between IPAH patients and healthy control to investigate the contribution of recruited immune cells in lung tissues to the development of IPAH with the hope of identifying potential biomarkers and therapeutic targets for IPAH.

2 | METHODS

2.1 | Sources of the gene data

GSE33463 and GSE48149 datasets were downloaded from Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/), and the detection platforms for both GSE33463 and GSE48149 datasets were Illumina human V3.0 Expression BeadChip (Edgar et al., 2002). The gene expression profiles of PBMCs from 30 IPAH patients were compared to 41 healthy volunteers. The gene expression profiles of lung tissues are available from 17 donors who underwent lung transplantation (Table 1). These previous studies can provide insightful viewpoints concerning the epidemiological characteristics and phenotyping data related to IPAH (Cheadle et al., 2012; Hsu et al., 2011). They were both used to explore the differentially expressed genes between IPAH patients and healthy controls. The workflow of this study is illustrated in Figure 1.

2.2 | Identification of the differentially expressed genes

R packages of “Illumina” and “limma” (http://www.bioconductor.org/packages/release/bioc/html/limma.html), provided by a Bioconductor project, were applied to assess GSE33463 and GSE48149 RAW datasets. We used
background correction, quantile normalization, probe summarization, and log2-transformation to create a robust multi-array average (RMA), a log-transformed perfect match, and a mismatch probe (PM and MM) methods. The Benjamin–Hochberg method was used to adjust original p-values, and the false discovery rate (FDR) procedure was used to calculate fold-changes (FC). Gene expression values of $2^{\log_{2} FC} > 2$ and adjusted $p < 0.05$ were used for DEGs of PBMCs; $2^{\log_{2} FC} > 1.5$ and adjusted $p < 0.05$ were used to identify DEGs of lung tissues. Then, two Volcano plots were adopted to visualize the expression differences by R 3.5.0. Additionally, we calculated and made Venn diagrams for co-DEGs for the two datasets.

### 2.3 Functional analysis

The PBMCs-DEGs and lung-DEGs were subjected for functional annotation and Gene Ontology/ Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) enrichment analysis for annotation, visualization, and integrated discovery of bioinformatics resources by DAVID (http://david.abcc.ncifcrf.gov/). GO terms and KEGG maps of biological functions associated with a $p < 0.05$ were significantly enriched. Besides, we presented different biofunctions of PBMC-DEGs and lung-DEGs in biological processes, molecular functions, and cellular components from DAVID, respectively.

### 2.4 Identification of protein–protein interaction (PPI) networks of DEGs

PPI networks of PBMCs-DEGs and lung-DEGs were analyzed using the search tool for retrieving interacting genes (STRING database, V10.5; http://string-db.org/) that can predict protein functional associations and protein–protein interactions. Subsequently, Cytoscape software (V3.5.1; http://cytoscape.org/) was applied to analyze biological networks and node degrees after downloading the analytic results of the STRING database.

### 2.5 Prediction of potential miRNAs for the co-DEGs

Finally, we applied online prediction tools utilizing mirDIP (http://ophid.utoronto.ca/mirDIP), miRDB (http://mirdb.org/), and mirWalk (http://mirwalk.umm.uni-heidelberg.de/) to predict potential miRNAs could target the co-DEGs in lung tissue and PBMCs, respectively. We then made a Venn diagram for the common potential miRNAs of the mirDIP, miRDB, and miRWalk.

### 3 RESULTS IDENTIFICATION OF DEGS

As indicated in Figure 2a, we found 251 DEGs in PBMCs of IPAH patients compared to healthy controls, including 110 downregulated genes and 141 upregulated genes. We found 151 DEGs in IPAH patients compared with the control population, including 73 downregulated and 78 upregulated genes in the lung tissues. The Volcano plots in Figure 2b illustrated the expression differences. And we identified six co-expressed DEGs based on the DEG overlaps between the two datasets (Figure 3). As indicated in Table 2, PDK4, RBPMS2, and PDE5A were upregulated in both PBMC and lung tissues from IPAH patients compared to healthy control. TNFAIP3, CCL3, and PHLD2 were found to be upregulated in lung tissue but downregulated in PBMCs.
3.1 | Functional GO terms and pathway enrichment analyses

The functional GO terms enrichment was performed to reveal IPAH-related GO categories such as biological processes, molecular functions, cellular components, and KEGG. For biological processes, we identified that the common between PBMCs with the lung tissues is apoptotic progress. For the cellular components, we found it were cytosol and mitochondrion. Their differentially expressed genes have common molecular functions in protein binding, protein homodimerization activity.

The top 10 GO terms of PBMCs-IPAH are shown in Table 3. For DEGs in PBMCs-IPAH, the most enriched GO terms of biological processes were associated with oxygen transport, blood coagulation, and apoptotic process. In the cellular component category, enriched GO terms were mainly associated with hemoglobin complex, platelet alpha granule membrane, and mitochondrion. Besides, GO terms enriched for DEGs in PBMCs-IPAH included oxygen transport activity, protein binding, and oxygen binding in the molecular function category. To explore the significant enrichment of DEGs of PBMCs-IPAH in pathway terms, we performed pathway
The DEGs of PBMCs-IPAH were enriched mainly in cytokine–cytokine receptor interaction, Toll-like receptor signaling pathway, NF-kappa B signaling pathway, and the chemokine signaling pathway. It is reported that oxygen transport activity plays a vital role in the vascular tone of pulmonary artery smooth muscle cells and hypoxia stimulates vasoconstriction of the pulmonary vascular (Wu et al., 2021). Cytokine–cytokine receptor interaction, chemokine signaling pathway, and Toll-like receptor signaling pathway are known drivers to pulmonary vascular remodeling and established PH (Farkas et al., 2019; Xiao et al., 2020). NF-kappa B signaling pathway has been reported as a therapeutic target for PH (Liu et al., 2020; Shi et al., 2018; Zhang et al., 2019; Zuo et al., 2020).

### TABLE 2  co-DEGs of PBMCs and lung tissues

| Gene     | logFC.PBMCs | logFC. Lung tissues |
|----------|-------------|---------------------|
| TNFAIP3  | -2.383422913| 2.467540092         |
| PDK4     | 1.479404085 | 2.194679977         |
| RBPMS2   | 1.249352733 | 0.741858209         |
| CCL3     | -1.167271751| 1.941109376         |
| PHLD1A   | -1.05684707 | 1.311408233         |
| PDE5A    | 1.005595159 | 0.7671995           |

Note: Red genes: co-upregulated genes in PBMCs and lung tissues; Black genes: inconsistently regulated genes between PBMCs and lung tissues.
| Category | ID          | Term                                           | Count | p value    |
|----------|-------------|------------------------------------------------|-------|------------|
| BP       | GO:0015671  | Oxygen transport                               | 6     | 9.09E−07   |
|          | GO:0007596  | Blood coagulation                              | 13    | 4.75E−06   |
|          | GO:0051607  | Defense response to virus                       | 12    | 9.64E−06   |
|          | GO:006915   | Apoptotic process                              | 22    | 1.42E−05   |
|          | GO:070098   | Chemokine-mediated signaling pathway           | 8     | 3.50E−05   |
|          | GO:2001240  | Negative regulation of extrinsic apoptotic      | 6     | 1.05E−04   |
|          |             | signaling Pathway in absence of ligand         |       |            |
|          | GO:006954   | Inflammatory response                          | 16    | 1.20E−04   |
|          | GO:032757   | Positive regulation of interleukin—8 production| 5     | 3.19E−04   |
|          | GO:010941   | Regulation of cell death                        | 4     | 3.21E−04   |
|          | GO:001774   | Microglial cell activation                      | 4     | 4.24E−04   |
| CC       | GO:0005833  | Hemoglobin complex                             | 7     | 3.20E−09   |
|          | GO:031092   | Platelet alpha granule membrane                 | 4     | 5.10E−04   |
|          | GO:0005829  | Cytosol                                        | 63    | 5.47E−04   |
|          | GO:0072562  | Blood microparticle                            | 8     | 0.003133417|
|          | GO:0000228  | Nuclear chromosome                             | 5     | 0.004393052|
|          | GO:000786   | Nucleosome                                     | 6     | 0.00665139 |
|          | GO:000788   | Nuclear nucleosome                             | 4     | 0.01776436 |
|          | GO:016234   | Inclusion body                                 | 3     | 0.021071293|
|          | GO:1990622  | CHOP-ATF3 complex                              | 2     | 0.02497475 |
|          | GO:0005739  | Mitochondrion                                  | 26    | 0.028572338|
| MF       | GO:0005344  | Oxygen transporter activity                     | 6     | 6.25E−07   |
|          | GO:0005515  | Protein binding                                | 149   | 1.28E−06   |
|          | GO:0019825  | Oxygen binding                                 | 6     | 3.38E−04   |
|          | GO:0046982  | Protein heterodimerization activity             | 16    | 0.001070882|
|          | GO:0042803  | Protein homodimerization activity              | 21    | 0.001278347|
|          | GO:0043565  | Sequence-specific DNA binding                  | 16    | 0.003068635|
|          | GO:000982   | Transcription factor activity, RNA polymerase II| 4     | 0.003108637|
|          |             | Promoter proximal region sequence-specific bin |       |            |
|          | GO:000809   | Chemokine activity                             | 5     | 0.003638514|
|          | GO:0003924  | GTPase activity                                | 9     | 0.011222782|
|          | GO:0008134  | Transcription factor binding                   | 10    | 0.01170829 |
| KEGG     | hsa05164    | Influenza A                                    | 13    | 2.75E−05   |
|          | hsa04060    | Cytokine–cytokine receptor interaction         | 13    | 6.49E−04   |
|          | hsa04380    | Osteoclast differentiation                      | 9     | 0.001415882|
|          | hsa05202    | Transcriptional misregulation in cancer        | 10    | 0.001726853|
|          | hsa04620    | Toll-like receptor signaling pathway           | 8     | 0.001801965|
|          | hsa05134    | Legionellosis                                  | 6     | 0.001895755|
|          | hsa04064    | NF-kappa B signaling pathway                   | 7     | 0.003082372|
|          | hsa04062    | Chemokine signaling pathway                    | 10    | 0.003588139|
|          | hsa05162    | Measles                                       | 8     | 0.006385733|
|          | hsa05160    | Hepatitis C                                    | 8     | 0.006385733|
The top 10 GO terms of lung-IPAH were performed and shown in Table 4. For DEGs in lung-IPAH, the most enriched GO terms of the biological process were associated with an apoptotic process, erythrocyte differentiation, DNA metabolic processes, regulation of growth, and metabolic process. In the cellular component category, enriched GO terms were mainly associated with hemoglobin complex, platelet alpha granule membrane, and cytosol. Furthermore, in the molecular function category, GO terms enriched for DEGs in lung-IPAH included metabolic pathways, biosynthesis of amino acids, lysosome, and carbon metabolism. To explore the significant enrichment of DEGs of lung-IPAH in pathway

| Category | ID                  | Term                                         | Count | p value       |
|----------|---------------------|----------------------------------------------|-------|---------------|
| BP       | GO:0006915          | Apoptotic process                            | 22    | 0.009726238   |
|          | GO:0030218          | Erythrocyte differentiation                   | 5     | 0.009950815   |
|          | GO:0016032          | Viral process                                 | 14    | 0.011693079   |
|          | GO:0006853          | Carnitine shuttle                             | 3     | 0.014621594   |
|          | GO:0016192          | Vesicle-mediated transport                    | 9     | 0.015859207   |
|          | GO:0006259          | DNA metabolic process                         | 4     | 0.017119889   |
|          | GO:0040008          | Regulation of growth                          | 5     | 0.025761733   |
|          | GO:0008152          | Metabolic process                             | 9     | 0.0270116     |
|          | GO:0006886          | Intracellular protein transport               | 11    | 0.029445951   |
|          | GO:0006183          | GTP biosynthetic process                      | 3     | 0.029961661   |
| CC       | GO:0070062          | Extracellular exosome                         | 99    | 1.70E−08      |
|          | GO:0005739          | Mitochondrion                                 | 53    | 3.35E−06      |
|          | GO:0005730          | Nucleolus                                     | 35    | 1.42E−04      |
|          | GO:0005829          | Cytosol                                       | 91    | 0.001448734   |
|          | GO:0005743          | Mitochondrial inner membrane                  | 20    | 0.001658054   |
|          | GO:0030131          | Clathrin adaptor complex                      | 4     | 0.003761553   |
|          | GO:0000139          | Golgi membrane                                | 23    | 0.004638949   |
|          | GO:0015629          | Actin cytoskeleton                            | 12    | 0.004950301   |
|          | GO:0005789          | Endoplasmic reticulum membrane                | 30    | 0.005118396   |
|          | GO:0005840          | Ribosome                                      | 10    | 0.00669396    |
| MF       | GO:0005515          | Protein binding                               | 219   | 7.77E−05      |
|          | GO:0003824          | Catalytic activity                            | 11    | 0.006071153   |
|          | GO:0004843          | Thiol-dependent ubiquitin-specific protease activity | 7 | 0.006401087   |
|          | GO:0004527          | Exonuclease activity                          | 4     | 0.006744449   |
|          | GO:0042803          | Protein homodimerization activity             | 26    | 0.010286664   |
|          | GO:0098641          | Cadherin binding involved in cell–cell adhesion | 13 | 0.018626355   |
|          | GO:0008135          | Translation factor activity, RNA binding      | 4     | 0.021853252   |
|          | GO:0008237          | Metallopeptidase activity                     | 6     | 0.026779975   |
|          | GO:0015078          | Hydrogen ion transmembrane transporter activity | 4 | 0.028323568   |
|          | GO:0030170          | Pyridoxal phosphate binding                   | 5     | 0.030629693   |
| KEGG     | hsa01100            | Metabolic pathways                            | 49    | 9.33E−04      |
|          | hsa01130            | Biosynthesis of antibiotics                   | 15    | 0.001017114   |
|          | hsa01230            | Biosynthesis of amino acids                   | 7     | 0.009966251   |
|          | hsa04142            | Lysosome                                      | 9     | 0.01213099    |
|          | hsa05100            | Bacterial invasion of epithelial cells        | 7     | 0.014459025   |
|          | hsa01200            | Carbon metabolism                             | 8     | 0.025410887   |
|          | hsa00230            | Purine metabolism                             | 10    | 0.036272174   |
|          | hsa04145            | Phagosome                                     | 9     | 0.038150082   |
terms, we performed pathway annotation of DEGs and obtained DEGs involved in all pathway terms in Table 4. The DEGs of lung-IPAH were enriched mainly with metabolic pathways, biosynthesis of antibiotics, biosynthesis of amino acids, and lysosome (Table 4). A recent 4-month, open-label study also showed that decreasing PDH(a metabolic-related molecular) has reduced mean PAP and PVR and improved functional capacity in IPAH patients with SIRT3 and UCP2 variants (Spiekerkoetter et al.,). Metabolic abnormalities cause PAH or are secondary to pulmonary vascular disease and subsequent RV failure (Paulin & Michelakis, 2014).

3.2 | PPI network analysis

We identified 176 and 103 nodes from the PPI network of PBMC- and lung tissue- IPAH DEGs, respectively (Figure 4a,b). Here, the hub nodes, CXCL8(degree38), JUN (degree37), TLR8(degree31), IL1B(degree29), and TLR7(degree26), are demonstrated with a relatively higher degree in PBMC (GSE33463). On the other side, hub genes of ENO1(degree17), STAT1(degree16), CXCL10(degree15), GPI (degree14), and IRF1(degree13) are associated as hub genes in related to lung tissue-IPAH.

3.3 | Predicted miRNAs of Co-DEGs

The potential miRNAs targeting the co-DEGs were predicted by mirDIP, miRDB, and mirWalk. We plotted a Venn diagram to identify the potential miRNAs for PDK4, RBPMS2, CCL3, and PDE5A, respectively (Table 5). The corresponding predicted miRNA coupled with PDK4 were hsa-miR-103a-3p and hsa-miR-148a-3p. The predicted miRNA targeted with RBPMS2 were hsa-miR-185-5p and hsa-miR-92, and PDE5A is coupled with hsa-miR-515-5p, hsa-miR-507, hsa-miR-19b-3p, hsa-miR-382-5p, and hsa-miR-300.

4 | DISCUSSION

IPAH is a progressive disorder characterized by progressive pulmonary arterial narrowing (Keating, 2016; Lau et al., 2017; Maron & Diagnosis, 2016). Although the pathogenesis of IPAH remains still unclear, increasing lines of evidence suggest that PBMCs may be involved in the pathogenesis of IPAH. It has been reported that PBMCs changes would be reflected by specific transcriptional changes in these cells in PAH patients (Cheadle et al., 2012; Hoffmann et al., 2016; Sarrion et al., 2015).

Endothelial progenitor cells, which belong to PBMCs, have been accumulating in the lung upon PH-induction (Yan et al., 2016). Moreover, bone marrow transplantation from PH mice to healthy mice increased the PA pressure in healthy mice (Levy et al., 2019; Nikolic & Yu, 2016). These may suggests that the changes in the PBMC genes might be the cause and effect of IPAH. Thus, we sought to explore the possible association between

**Figure 4** PPI network. PPI networks from a and b were constructed using the STRING database for DEGs related to PBMCs and lung tissues, respectively (threshold>0.5). a. CXCL8, JUN, and TLR8 could be implicated as the hub genes in PBMCs. b. ENO1, STAT1, and CXCL10 could be implicated as the hub genes in lung tissues.
PBMCs and lung tissues in IPAH with the hope of identifying potential biomarkers or novel therapeutic targets for IPAH.

For DEGs in PBMCs-IPAH, the most enriched GO terms of biological processes and molecular functions were associated with the oxygen transport activity and oxygen binding. Given the fact that the lung is the major organ for oxygen transport, our findings might suggest a possible relationship between PBMCs and lung tissues concerning oxygen transportation. Some studies have shown that in IPAH patients, due to increased PVR, the right ventricle’s compensation is not enough (decreased cardiac output) to meet the demand for oxygen transport, resulting in inefficient lung gas exchange, and low perfusion (Tang et al., 2017).

Apart from the genes that are not consistent with up-regulation and downregulation, there still remain four genes altered in both PBMCs and lung tissues from IPAH patients compared to healthy controls, including PDK4, RBPMS2, and PDE5A, which are all upregulated in IPAH patients.

Among these genes, PDE5A has been used as a target for IPAH therapy, including drug such as sildenafil, tadalafil, vardenoafil, and so on. PDE5A is a phosphodiesterase specifically binding to cGMP, which is the main enzyme that metabolizes cGMP. Previous studies on PH animal models and PASMC from IPAH patients have shown that PDE5A participates in the excessive proliferation of PASMC. Wharton et al. demonstrated that PDE5A inhibition decreases DNA synthesis via increasing cellular cGMP level and stimulated the apoptosis of human PASMC (Lan et al., 2018; Osinski et al., 2001; Rai et al., 2018; Wharton et al., 2005).

PDK4, a gene coding for an enzyme that suppresses the mitochondrial activity in favor of glycolysis. Yuan K et al. found that increased PDK4 is associated with PAH pericyte hyperproliferation and reduced endothelial-pericyte interactions (Yuan et al., 2016). Piao et al. showed that pyruvate dehydrogenase kinase (PDK) is activated in the right ventricular hypertrophy (RVH), causing an increase in glycolysis relative to glucose oxidation that impairs the right ventricular function (Piao et al., 2013). However, another DEG, RBPMS2, to the best of our knowledge, has not been reported to be associated with IPAH. Several studies have shown that RBPMS2 is related to the plasticity of the smooth muscle cells. Akkerberg et al. have demonstrated that the proteins encoded by RBPMS2 may play a key role in regulating the cardiomyocyte differentiation, proliferation, survival, and/or contractility (Kaufman et al., 2018). Sagnol et al. demonstrated that RBPMS2 is related to stomach smooth muscle development and plasticity. The excessive proliferation of vascular smooth muscle is one of the main pathological changes of PH (Sagnol et al., 2016), the relevant mechanisms of RBPMS2 in PAH development need to be further explored.

These findings suggest that the expression of PDK4, RBPMS2, and PDE5A in PBMCs could predict the expression levels of these genes in lung tissues and might serve
as circulating potential biomarkers and/or therapeutic targets for IPAH patients. Further evaluation is ongoing in our group to provide more solid evidence to determine whether these DEGs could serve as biomarkers and/or therapeutic targets for IPAH.

5 | CONCLUSION

These findings demonstrate the expression of PDK4, RBPMS2, and PDE5A in PBMCs could predict the expression levels of these genes in lung tissue and might serve as circulating biomarkers for IPAH.

5.1 | Limitation

The clinical characteristics of patients were collected from the GEO database. The fundamental limitation is the lack of ethnic or geographic diversity in our samples, which may affect the reliability of the results. In addition, since the GEO dataset of PBMCs or lung tissues of IPAH are very limited, and the datasets belonging to the same probe-type are even less, we selected two datasets with the largest sample size to analyze the differentially expressed genes. Further studies with larger sample sizes, more diverse ethnicities, and less heterogeneity are warranted to test our hypothesis.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China, the National Key Research and Development Program of China, Guangdong Outstanding Young Scientist Funding, and the Science and Technology Program of Guangzhou.

CONFLICT OF INTEREST

No potential conflict of interest was disclosed.

AUTHOR CONTRIBUTION

Study Design: Wenjun He, Xi Su, Tao Wang, and Jian Wang. Data Analysis: Wenjun He, Xi Su, Lingdan Chen, and Chunli Liu. Manuscript writing: Wenjun He, Xi Su, and Wenju Lu. All authors approved the final version of the manuscript, agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed. All authors contributed to data interpretation, manuscript writing, and critical analysis of the manuscript; and provided final approval for manuscript submission.

GUARANTOR

Jian Wang and Tao Wang.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. Discovery cohort and duplication cohort (GSE33463 and GSE48149) were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo/).

ORCID

Wenjun He https://orcid.org/0000-0003-1307-3455
Jian Wang https://orcid.org/0000-0002-1278-256X

REFERENCES

Baine, M. J., Menning, M., Smith, L. M., Mallya, K., Kaur, S., Rachagani, S., Chakraborty, S., Sasson, A. R., Brand, R. E., & Batra, S. K. (2012). Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. *Cancer Biomarkers, 11*(1), 1–14. https://doi.org/10.3233/cbm-2012-0260

Castaldo, I., De Rosa, M., Romano, A., Zuchegna, C., Squitieri, F., Mechelli, R., Peluso, S., Borrelli, C., Del Mondo, A., Salvatore, E., Vescovi, L. A., Migliore, S., De Michele, G., Ristori, G., Romano, S., Avvedimento, E. V., & Porcellini, A. (2019). DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease. *Annals of Neurology, 85*, 296-301. https://doi.org/10.1002/ana.25393

Cheadle, C., Berger, A. E., Mathai, S. C., Grigoryev, D. N., Watkins, T. N., Sugawara, Y., Barkataki, S., Fan, J., Boorgula, M., Hummers, L., Zaiman, A. L., Girgis, R., McDevitt, M. A., Johns, R. A., Wigley, F., Barnes, K. C., & Hassoun, P. M. (2012). Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients. *PLoS One, 7*(4), e34951. https://doi.org/10.1371/journal.pone.0034951

Chesne, J., Danger, R., Botturi, K., Reynaud-Gaubert, M., Musсот, S., Stern, M., Danner-Boucher, I., Mornex, J.-F., Pison, C., Dromer, C., Kessler, R., Dahan, M., Brugière, O., Le Pavec, J., Perros, F., Humbert, M., Gomez, C., Brouard, S., & Magnan, A. (2014). Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. *PLoS One, 9*(10), e109291. https://doi.org/10.1371/journal.pone.0109291

Edgar, R., Domrachev, M., & Lash, A. E. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Research, 30*(1), 207–210. https://doi.org/10.1093/nar/30.1.207

Farkas, D., Thompson, A. A. R., Bhagwani, A. R., Hultman, S., Ji, H., Kotha, N., Farr, G., Arnold, N. D., Brithwaite, A., Cashbolt, H., Cole, J. E., Sabroe, I., Monaco, C., Cool, C. D., Goncharova, E. A., Lawrie, A., & Farkas, L. (2019). Toll-like receptor 3 is a therapeutic target for pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine, 199*(2), 199–210. https://doi.org/10.1164/rccm.201707-13700C

Foris, V., Kovacs, G., Marsh, L. M., Bălînt, Z., Tötsch, M., Avian, A., Douschan, P., Ghanim, B., Klepetko, W., Olschewski, A., & Olschewski, H. (2016). CD133+ cells in pulmonary arterial hypertension. *European Respiratory Journal, 48*, 459-469. https://doi.org/10.1183/13993003.01523-2015
Goleva, E., Babineau, D. C., Gill, M. A., Jackson, L. P., Shao, B., Hu, Z., Liu, A. H., Visness, C. M., Sorkness, C. A., Leung, D. Y. M., Togias, A., & Busse, W. W. (2019). Expression of corticosteroid-regulated genes by PBMCs in children with asthma. *Journal of Allergy and Clinical Immunology, 143*(3), 940–947.e6. https://doi.org/10.1016/j.jaci.2018.06.043

Guo, G., Wang, H., Ye, L., Shi, X., Yan, K., Lin, K., Huang, Q., Li, B., Lin, Q., Zhu, L., Xue, X., & Zhang, H. (2019). Hsa_circ_0000479 as a novel diagnostic biomarker of systemic lupus erythematosus. *Frontiers in Immunology, 10*, 2281. https://doi.org/10.3389/fimmu.2019.02281

Hassoun, P. M., Mouthon, L., Barbera, J. A., Eddahibi, S., Flores, S. C., Grimminger, F., Jones, P. L., Maitland, M. L., Michelakis, E. D., Morrell, N. W., Newman, J. H., Rabinovitch, M., Schermuly, R., Stenmark, K. R., Voelkel, N. F., Yuan, J.-X., & Humbert, M. (2009). Inflammation, growth factors, and pulmonary vascular remodeling. *Journal of the American College of Cardiology, 54*(1), S10–S19. https://doi.org/10.1016/j.jacc.2009.04.006

Hoffmann, J., Wilhelm, J., Olszewski, A., & Kwapiszewska, G. (2016). Microarray analysis in pulmonary hypertension. *European Respiratory Journal, 48*(1), 229–241. https://doi.org/10.1183/13993003.02030-2015

Hoffmann, J., Yin, J., Kukucka, M., Yin, N., Saarikko, I.,Sterner-Kock, A., Fujii, H., Leong-Poi, H., Kuppe, H., Schermuly, R. T., & Kuebler, W. M. (2011). Mast cells promote lung vascular remodelling in pulmonary hypertension. *European Respiratory Journal, 37*(6), 1400–1410. https://doi.org/10.1183/0903936.00043310

Hsu, E., Shi, H., Jordan, R. M., Lyons-Weiler, J., Pilewski, J. M., & Feghali-Bostwick, C. A. (2011). Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. *Arthritis & Rheumatism, 63*(3), 783–794. https://doi.org/10.1002/art.30159

Kaufman, O. H., Lee, K., Martin, M., Rothhämel, S., & Marlow, F. L. (2018). rbpms2 functions in Balbiani body architecture and ovary fate. *PLOS Genetics, 14*(7), e1007489. https://doi.org/10.1371/journal.pgen.1007489

Keating, G. M. (2016). Macitentan: A review in pulmonary arterial hypertension. *American Journal of Cardiovascular Drugs, 16*(6), 453–460. https://doi.org/10.1007/s40256-016-0188-x

Khan, S., & Kaithra, K. A. (2019). Single-cell RNA-sequencing of peripheral blood mononuclear cells with ddSEQ. *Methods in Molecular Biology, 1979*, 155-176. https://doi.org/10.1007/978-1-4939-29420_10

Lan, T. H., Chen, X. L., Wu, Y. S., Qiu, H.-L., Li, J.-Z., Ruan, X.-M., Xu, D.-P., & Lin, D.-Q. (2018). 3,7-Bis(2-hydroxyethyl)caritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats. *European Journal of Pharmacology, 829*, 102–111 https://doi.org/10.1016/j.ejphar.2018.04.011

Lau, E. M. T., Giannoulatou, E., Celermajer, D. S., Humbert, M. (2017). Epidemiology and treatment of pulmonary arterial hyperten- sion. *Nature Reviews Cardiology, 14*(10), 603–614. DOI: https://doi.org/10.1038/nrcardio.2017.84

Lenna, S., Farina, A. G., Martynov, V., Christmann, R. B., Wood, T. A., Farber, H. W., Scorza, R., Whitfield, M. L., Layfais, R., & Trojanowska, M. (2013). Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension.

Arthritis & Rheumatism, 65(5), 1357–1366. https://doi.org/10.1002/art.37891

Levy, M., Moshous, D., Szczepanski, I., Galmiche, L., Castelle, M., Lesage, F., Dupic, L., Neven, B., Fischer, A., Blanche, S., & Bonnet, D. et al (2019). Pulmonary hypertension after bone marrow transplantation in children. *European Respiratory Journal, 54*(5), 1900612. https://doi.org/10.1183/13993003.00612-2019

Liu, J., Li, J., Xie, C., Xuan, L., & Tang, B. (2020). MSCs attenuate hypoxia induced pulmonary hypertension by activating P53 and NF-kB signaling pathway through TNFalpha secretion. *Biochemical and Biophysical Research Communication, 532*, 400–405. https://doi.org/10.1016/j.bbrc.2020.08.064

Maron, B. A., & Diagnosis, G. N. (2016). Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era. *JAMA Cardiology, 1*(9), 1056–1065. https://doi.org/10.1001/jamaCARDIO.2016.4471

Marsh, L. M., Jandl, K., Grunig, G., Foris, V., Bashir, M., Ghanim, B., Klepetko, W., Olszewski, H., Olszewski, A., & Kwapiszewska, G. (2018). The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension. *European Respiratory Journal, 51*(1), 170124. https://doi.org/10.1183/13993003.01214-2017

Nikolic, I., & Yu, P. B. (2016). The role of bone marrow–derived cells in pulmonary arterial hypertension. What lies beneath? *American Journal of Respiratory and Critical Care Medicine, 193*(8), 822–824. https://doi.org/10.1164/rcrm.2015112293ED

Osininski, M. T., Rauch, B. H., & Schor, K. (2001). Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. *Molecular Pharmacology, 59*(5), 1044–1050. https://doi.org/10.1124/mol.59.5.1044

Paulin, R., & Michelakis, E. D. (2014). The metabolic theory of pulmonary arterial hypertension. *Circulation Research, 115*(1), 148–164. https://doi.org/10.1161/CIRCRESAHA.115.301130

Perros, F., Dorfmuller, P., Souza, R., Durand-Gasselin, I., Mussot, S., Mazmanian, M., Herve, P., Emilie, D., Simonneau, G., & Humbert, M. (2007). Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. *European Respiratory Journal, 29*(3), 462–468. https://doi.org/10.1183/09031936.0009470

Piao, L., Sidhu, V. K., Fang, Y. H., Ryan, J. J., Parikh, K. S., Hong, Z., Toth, P. T., Morrow, E., Kutty, S., Lopaschuk, G. D., & Archer, S. L. (2013). FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: Therapeutic benefits of dichloacetate. *Journal of Molecular Medicine, 91*(3), 333–346. https://doi.org/10.1007/s00109-012-0982-0

Pienn, M., Burgard, C., Payer, C., Avian, A., Urschler, M., Stollberger, R., Olszewski, A., Olszewski, H., Johnson, T., Meinel, F. G., & Bälint, Z. (2018). Healthy lung vessel morphology derived from thoracic computed tomography. *Frontiers in Physiology, 9*, 346. https://doi.org/10.3389/fphys.2018.00346

Rai, N., Veeroju, S., Schymura, Y., Janssen, W., Wietelmann, A., Kojonazarov, B., Weissmann, N., Stasch, J.-P., Ghofrani, H. A., Seeger, W., Schermuly, R. T., & Novoyatleva, T. (2018). Effect of riociguat and sildenafil on right heart remodeling and function in pressure overload induced model of pulmonary arterial banding. *BioMed Research International, 2018*, 1–9. https://doi.org/10.1155/2018/3293584

Risbano, M. G., Meadows, C. A., Coldren, C. D., Jenkins, T. J., Edwards, M. G., Collier, D., Huber, W., Mack, D. G.,
Fontenot, A. P., Geraci, M. W., & Bull, T. M. (2010). Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension. *Clinical and Translational Science*, 3(5), 210–218. https://doi.org/10.1111/j.1752-8062.2010.00218.x

Sagnol, S., Marchal, S., Yang, Y., Allemand, F., & de Santa Barbara, P. (2016). Epithelial splicing regulatory protein 1 (esrpi) is a new regulator of stomach smooth muscle development and plasticity. *Developmental Biology*, 414(2), 207–218. https://doi.org/10.1016/j.ydbio.2016.04.015

Sarrion, I., Milian, L., Juan, G., Ramon, M., Furest, I., Carda, C., Cortijo Gimeno, J., & Mata Roig, M. (2015). Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a. *Oxidative Medicine and Cellular Longevity*, 2015, 1–10. https://doi.org/10.1155/2015/792846

Savai, R., Pullamsetti, S. S., Kolbe, J., Bieniek, E., Voswinckel, R., Fink, L., Scheed, A., Ritter, C., Dahal, B. K., Vater, A., Klussmann, S., Ghofrani, H. A., Weissmann, N., Klepetko, W., Banat, G. A., Seeger, W., Grimminger, F., & Schermuly, R. T. (2012). Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, 186(9), 897–908. https://doi.org/10.1164/rccm.201202-0335OC

Shi, W., Zhai, C., Feng, W., Wang, J., Zhu, Y., Li, S., Wang, Q., Zhang, Q., Yan, X., Chai, L., Liu, P., Chen, Y., & Li, M. (2018). Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-kappaB activation. *Life Science*, 210, 140-149. https://doi.org/10.1016/j.lfs.2018.08.071

Spiemakerkoetter, E., Kawut, S. M., & de Jesus Perez, V. A. (2019). New and emerging therapies for pulmonary arterial hypertension. *Annual Review of Medicine*, 70(1), 45–59. https://doi.org/10.1146/annurev-med-041717-085955

Tang, Y., Luo, Q., Liu, Z., Ma, X., Zhao, Z., Huang, Z., Gao, L., Jin, Q., Xiong, C., & Ni, X. (2017). Oxygen uptake efficiency slope predicts poor outcome in patients with idiopathic pulmonary arterial hypertension. *Journal of the American Heart Association*, 6(7), e005037. https://doi.org/10.1161/jaha.116.005037

Wharton, J., Strange, J. W., Moller, G. M., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C., & Wilkins, M. R. (2005). Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. *American Journal of Respiratory and Critical Care Medicine*, 172(1), 105–113. https://doi.org/10.1164/rccm.200411-1587OC

Wu, D., Dasgupta, A., Read, A. D., Bentley, R. E. T., Motamed, M., Chen, K.-H., Al-Qazazi, R., Mewburn, J. D., Dunham-Snary, K. J., Alizadeh, E., Tian, L., & Archer, S. L. (2021). Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer. *Free Radical Biology and Medicine*, 170, 150–178. https://doi.org/10.1016/j.freeradbiomed.2020.12.452

Xiao, G., Wang, T., Zhuang, W., Ye, C., Luo, L., Wang, H., Lian, G., & Xie, L. (2020). RNA sequencing analysis of monocrotaline-induced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways. *Aging*, 12(6), 4953–4969. https://doi.org/10.18632/aging.102922

Yamamoto, T. (2011). Autoimmune mechanisms of scleroderma and a role of oxidative stress. *Self/Nonself*, 2(1), 4. https://doi.org/10.4161/self.2.1.14058

Yan, L., Chen, X., Talati, M., Nunley, B. W., Gladson, S., Blackwell, T., Cogan, J., Austin, E., Wheeler, F., Loyd, J., West, J., & Hamid, R. (2016). Bone marrow–derived cells contribute to the pathogenesis of pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, 193(8), 898–909. https://doi.org/10.1164/rccm.201502-0407OC

Yang, B., Liu, Z., Ning, H., Zhang, K., Pan, D., Ding, K., Huang, W., Kang, X.-L., Wang, Y., & Chen, X. (2016). MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer. *Cancer Biomarkers*, 17(2), 223–230. https://doi.org/10.3233/cbm-160634

Yeager, M. E., Nguyen, C. M., Belchenko, D. D., Colvin, K. L., Takatsuki, S., Ivy, D. D., & Stenmark, K. R. (2012). Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. *European Respiratory Journal*, 39(1), 104–111. https://doi.org/10.1183/09031936.00072311

Yuan, K., Shao, N. Y., Hennigs, J. K., Discipulo, M., Orcholski, M. E., Shamskhou, E., Richter, A., Hu, X., Wu, J. C., & de Jesus Perez, V. A. (2016). Increased pyruvate dehydrogenase kinase 4 expression in lung pericytes is associated with reduced endothelial-pericyte interactions and small vessel loss in pulmonary arterial hypertension. *The American Journal of Pathology*, 186(9), 2500–2514. https://doi.org/10.1016/j.ajpath.2016.05.016

Zhang, H., Lin, Y., Ma, Y., Zhang, J., Wang, C., & Zhang, H. (2019). Protective effect of hydrogen sulfide on monocrotaline-induced pulmonary arterial hypertension via inhibition of the endothelial mesenchymal transition. *International Journal of Molecular Medicine*, 44, 2091–2102. https://doi.org/10.3892/ijmm.2019.4359

Zuo, Z. T., Ma, Y., Sun, Y., Bai, C. Q., Zhou, H. Y., & Chen, B. H. (2020). Role of TLR4/NF-kappaB signalling pathway in pulmonary arterial hypertension in patients with chronic obstructive pulmonary disease. *Journal of the College of Physicians and Surgeons Pakistan*, 30: 568-573. https://doi.org/10.29271/jcpsp.2020.06.568

How to cite this article: He, W., Su, X., Chen, L., Liu, C., Lu, W., Wang, T., & Wang, J. (2022). Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension. *Physiological Reports*, 10, e15101. https://doi.org/10.14814/phy2.15101